VOLITIONRX LTD (VNRX): Unregistered Sales of Equity Securities
VOLITIONRX LTD (VNRX) filed an SEC Form 8-K — Unregistered Sales of Equity Securities. Item 3.02 Unregistered Sales of Equity Securities Conversions of Notes As previously reported, pursuant to that certain securities purchase agreement dated May 15, 2025 (as amended and restated on January 7, 2026, the “SPA”), VolitionRx Limited (the “Company”) issued to Lind Glob
How this was made
The 30-second read
Why it matters
The conversion adds ~1.4 M shares, increasing total outstanding shares to ~27.9 M, modestly diluting existing holders.
Market read
Primary disclosure of a small equity dilution event; limited immediate trading relevance.
What to watch
Potential future financing needs if additional conversions occur.
Background
VolitionRx Ltd filed a Form 8‑K disclosing unregistered sales of equity securities arising from note conversions.
Ticker impact
SEC 8‑K reports conversion of notes into ~1.4 M shares of common stock, a new unregistered equity sale.
minor downward pressure
Small conversion amounts relative to total shares; no cash inflow, only dilution.
Market effects
Limited impact on biotech sector; similar convertible note conversions are common.
None
None
Counterpoint
Investors may view the dilution as a sign of cash constraints, but the conversion could improve balance‑sheet flexibility.
Key entities
- companyVolitionRx Ltd
Biopharma company issuing convertible notes.
- investorLind Global Asset Management XII LLC
Holder of the convertible notes.
